Literature DB >> 2213822

Structure-based, C2 symmetric inhibitors of HIV protease.

D J Kempf1, D W Norbeck, L Codacovi, X C Wang, W E Kohlbrenner, N E Wideburg, D A Paul, M F Knigge, S Vasavanonda, A Craig-Kennard.   

Abstract

Mesh：

Substances：

Year:  1990        PMID： 2213822     DOI： 10.1021/jm00172a002

Source DB:  PubMed          Journal:  J Med Chem        ISSN： 0022-2623            Impact factor:   7.446


× No keyword cloud information.
  21 in total

1.  Antiviral and pharmacokinetic properties of C2 symmetric inhibitors of the human immunodeficiency virus type 1 protease.

Authors:  D J Kempf; K C Marsh; D A Paul; M F Knigge; D W Norbeck; W E Kohlbrenner; L Codacovi; S Vasavanonda; P Bryant; X C Wang
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

3.  Solvent accessibility as a predictive tool for the free energy of inhibitor binding to the HIV-1 protease.

Authors:  V Nauchitel; M C Villaverde; F Sussman
Journal:  Protein Sci       Date:  1995-07       Impact factor: 6.725

4.  Asymmetric dihydroxylation route to a dipeptide isostere of a protease inhibitor: enantioselective synthesis of the core unit of ritonavir.

Authors:  Arun K Ghosh; Dongwoo Shin; Packiarajan Mathivanan
Journal:  Chem Commun (Camb)       Date:  1999       Impact factor: 6.222

5.  Human immunodeficiency virus type 1 proteinase resistance to symmetric cyclic urea inhibitor analogs.

Authors:  U Nillroth; L Vrang; P O Markgren; J Hultén; A Hallberg; U H Danielson
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans.

Authors:  D J Kempf; K C Marsh; J F Denissen; E McDonald; S Vasavanonda; C A Flentge; B E Green; L Fino; C H Park; X P Kong
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  In vitro anti-human immunodeficiency virus (HIV) activity of XM323, a novel HIV protease inhibitor.

Authors:  M J Otto; C D Reid; S Garber; P Y Lam; H Scarnati; L T Bacheler; M M Rayner; D L Winslow
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 8.  Anti-AIDS drug development: challenges and strategies.

Authors:  P Mohan
Journal:  Pharm Res       Date:  1992-06       Impact factor: 4.200

9.  In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.

Authors:  M J Otto; S Garber; D L Winslow; C D Reid; P Aldrich; P K Jadhav; C E Patterson; C N Hodge; Y S Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  1993-08-15       Impact factor: 11.205

10.  Preclinical evaluation of antiviral activity and toxicity of Abbott A77003, an inhibitor of the human immunodeficiency virus type 1 protease.

Authors:  J J Kort; J A Bilello; G Bauer; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.